Funding Guidelines

2025 Funding Round

Program website: BioMedTech Incubator – Brandon BioCatalyst

Contact: info@cureator.com.au

CUREator, delivered by Brandon BioCatalyst, in partnership with Australia's national science agency CSIRO, is supported by the Australian Government's Medical Research Future Fund (MRFF) through the Department of Health, Disability and Ageing to deliver the BioMedTech Incubator (BMTI) 2024 Program.

October 2025

Table of Contents

1 About Us

1.1 About CUREator

CUREator is a national biotechnology incubator delivered by Brandon BioCatalyst that supports Australian biomedical research and innovation with commercial potential. Funded by the Medical Research Future Fund (MRFF) and Australia's national science agency, CSIRO, CUREator provides grant funding programs to opportunities spanning from drug discovery research through to clinical development. Funding is structured like an investor, with clear funding tranches aligned to key value-adding and de-risking development milestones. CUREator works closely with project teams, providing scientific and commercial expertise, networks and hands-on guidance to support projects through the early development phases and achieve key outcomes.

https://brandonbiocatalyst.com/cureator/

1.2 About Brandon BioCatalyst and Brandon Capital

Brandon Capital is Australasia's leading life science venture capital firm, with a solid global presence supported by key partnerships and team members across the US and UK. Brandon Capital supports life science companies from early-stage seed investment to expansion capital from proof-of-concept to commercialisation.

Managed by Brandon Capital, Brandon BioCatalyst is a unique collaboration of over 50 leading medical research institutes, investors, and government united by a single purpose: progressing the next generation of medical therapies and technology that improve health and save lives.

www.brandoncapital.vc | www.brandonbiocatalyst.com

1.3 About CSIRO

CSIRO is Australia's national science agency and innovation catalyst. We solve the greatest challenges through innovative science and technology. Our collaborative research turns science into solutions for food security and quality; clean energy and resources; health and wellbeing; resilient and valuable environments; innovative industries; and a secure Australia and region.

https://www.csiro.au/

2 CUREator program

2.1 Program overview

CUREator in partnership with CSIRO is delivering a national program to accelerate the development and maturation of early-stage therapeutic innovations across the drug discovery, preclinical and clinical development stages addressing significant unmet medical needs. CUREator is funded by the Australian Government's Medical Research Future Fund (MRFF) through the Department of Health, Disability and Ageing to deliver the BioMedTech Incubator (BMTI) 2024 program.

As Australia's leading life sciences incubator, CUREator has been designed to assist in overcoming translational challenges in the Australian biomedical technology sector. By bridging the gap between research and investment, CUREator supports projects to deliver mutually agreed, milestone-based funding activities. These activities are informed by technical and commercial experts to ensure potential therapies are best placed to achieve success and advance towards commercialisation, providing patient benefit and a return on investment in medical research.

2.2 Program design

CUREator will support promising Australian biotech companies developing novel therapeutics across the drug discovery, preclinical and clinical development stages that address significant unmet medical needs with strong commercial potential.

Successful small-to-medium enterprises (SMEs) will gain access to significant non-dilutive capital (up to $5 million per project), commercial and scientific guidance, international expertise and networks, hands-on support, and mentorship to drive the translation and commercialisation of early-stage therapeutics. Each project will be developed with expert input, with clearly defined, mutually agreed, project milestones that deliver key value-adding outcomes. Structured using an investor's perspective, performance accountability will be embedded into the program with funding released in tranches upon the attainment of milestones that are designed to progress the opportunity on the critical path to commercialisation. SMEs will have access to several nationwide training programs from Brandon BioCatalyst and CSIRO, workshops and mentoring programs to access sector expertise, connect with peers, improve commercial acumen and raise their profile. By aligning funding incentives, milestone-driven progress and commercial development, SMEs will be supported to secure follow-on funding and facilitate their continued development to ultimately nurture the next generation of innovators, improve patient outcomes, create jobs and grow the Australian biotech ecosystem.

CUREator will conduct two open, competitive funding rounds for SME cohort intakes (Stage 1 funding) during the five-year BMTI program. The first round opens in 2025, and key dates are outlined in Key dates for the first round.

CUREator adopts the established multi-stage review processes of the Brandon BioCatalyst investment model, ensuring thorough due diligence, expert advice, and independent investment insights.

2.3 Project profile

CUREator is seeking innovative Australian therapeutic projects that demonstrate the potential to progress from early-stage research and development to investable, commercially attractive opportunities. The program will support the preclinical, clinical and/or commercial development of new therapeutic agents and novel uses for existing drugs with commercial potential. Therapeutic development activities will range from target identification and validation, compound screening, optimisation and lead selection, mechanism of action studies, proof-of-concept experiments, formal preclinical development, clinical trials, indication selection and commercial positioning and validation.

Therapeutics covers various modalities, including small molecules, monoclonal antibodies, gene and cell therapies, RNA drugs, antibody-drug conjugates, biologics, targeted protein degraders, nanobodies, theranostics and emerging modalities.

In general, successful applications will:

- Address a significant unmet need with a clear path to patient impact and market potential
- Be highly differentiated from existing standard of care and emerging competitor products
- Present a credible, milestone-driven development plan that de-risks the opportunity and positions the SME for partnering, commercialisation or follow-on investment
- Show strong commercial potential supported by a clear intellectual property (IP) position and protection strategy as well as considered commercialisation pathways
- Be led by a capable and committed team with access to the required resources and organisational support to deliver on the proposed project.

3 Eligibility criteria and requirements

3.1 Eligible applicants

- Applicants must be:
  - An Australian SME that is private or public, listed or unlisted (Pty Ltd. or Ltd.). An Australian SME is defined as a for-profit business that employs less than 200 people, is based in Australia and is a registered Australian corporate entity (i.e., registered with ASIC).
  - Researcher(s) at an Australian university or research institute and if successful, will incorporate a new company (NewCo) that meets the above SME requirements prior to the award of funding.
- Applicants must own or have exclusive rights to the background and project intellectual property (IP) relevant to the project.
- Applicants must provide a letter of support from their:
  - Board or CEO for established companies, or
  - Business development manager/tech transfer office for researchers.

- Applicants must be willing to commercialise the technology.

3.2 Application submission

Only one application may be submitted by the same SME entity.

Universities, research institutes or other publicly funded research organisations (PFROs) may submit applications on behalf of multiple projects within their organisation. Where universities, research institutes or other PFROs are coordinating proposals on behalf of multiple projects, the project (and ABN/ACN, if applicable) must be clearly identified and distinguishable for each application.

3.3 Ineligible applicants

Unfortunately, not-for-profit organisations (NFPs), university TTO's/IP holding companies, companies incorporated outside of Australia, Australian companies with 200 or more employees are not eligible to be awarded funding. These organisations may apply to the program on behalf of projects within their organisation but only if there is the intent to incorporate a for-profit entity that meets the grant requirements if successful. These criteria reflect the requirements of the Medical Research Future Fund (MRFF) grant that CUREator operates.

4 Project funding

CUREator will provide up to a maximum of $5 million per project over two funding stages.

4.1 Stage 1 – Initial project funding

Stage 1 funding available will depend on the maturity level of the opportunity:

- **Preclinical opportunities:** $1 million to $1.5 million

Funding at the preclinical stage supports research and development activities required to advance a commercial opportunity toward clinical readiness. Eligible activities may include: key proof-of-concept experiments, mechanism of action studies, target identification and validation, hit-to-lead, lead optimisation and selection, formal development planning, indication selection and activities focused on commercial positioning and/or validation activities.

- **Clinical opportunities:** $1 million to $2.5 million

Funding at the clinical stage supports the clinical development of therapeutics. Eligible activities may include: preparation, initiation and completion of Phase 1 and/or Phase 2 clinical studies, including investigator lead, and multi-centre studies. Studies may be designed to evaluate safety and tolerability, and generate evidence of efficacy and/or biomarker response.

Successful SMEs will have up to two years to complete Stage 1 project activities agreed upon as part of the application and selection process.

4.2 Stage 2 – Top-up funding

Top-up funding (up to a maximum total of $5 million per project across Stages 1 and 2) will be available on a competitive basis to successful SMEs who achieve their milestones during the Stage 1 period. Top-up funding will enable follow-on funding for promising projects to continue their momentum. Successful projects will have a maximum total of 4 years to complete Stage 1 and 2 project activities and achieve agreed milestones.

4.3 Milestone-driven, tranche funding payments

Funding is structured like an investor such that funding is released in tranches and upon the attainment of technical and commercial 'go/no-go' milestones within timelines designed to progress the SMEs' journey to commercialisation.

Given the milestone-based funding, some SMEs may not meet milestones early in their development program and may not continue to be funded.

5 Use of CUREator funding

Any funding provided by CUREator needs to abide by the eligible expenditure funding rules applied by the MRFF. Accordingly, the following guidelines are provided for your reference in terms of eligible and ineligible expenditure. Please ensure your application project and budget adheres to these guidelines.

5.1 Eligible use of funds

You can only spend grant funds on eligible expenditure you have incurred on an agreed project as defined in your grant agreement. If your application is successful, we may ask you to verify project costs that were provided in your application. You may need to provide evidence such as quotes or invoices for major costs.

Not all expenditure on your project may be eligible for grant funding. The CUREator team may be able to give additional guidance on eligible expenditure if required. To be eligible, expenditure must be a direct cost of the project, or be incurred by you for required project audit activities. Companies must also incur the project expenditure between the project start and end date for it to be eligible, unless stated otherwise.

5.1.1 *Eligible expenditure*

- Direct labour costs of employees directly employed on the core elements of the project, with a demonstrated and monitored link to project objectives and outcomes. Leadership or administrative staff costs, provided there are direct, demonstrated and monitored links to project objectives and outcomes, are limited to 10 per cent of the total amount of eligible labour expenditure claimed. You cannot calculate labour costs by estimating the employee's worth. If you have not exchanged money (either by cash or bank transactions) we will not consider the cost eligible.
- Eligible salary expenditure includes an employee's total remuneration package as stated on their Pay As You Go (PAYG) Annual Payment Summary submitted to the ATO.
- The maximum full-time equivalent salary for an employee, including packaged components, that you can claim through the grant is $175,000 per annum. You can only claim eligible salary costs when an employee is working directly on agreed project activities, for the actual time spent on the project, during the agreed project period.
- You may include eligible salary costs such as employer paid superannuation, payroll tax, workers compensation insurance, and leave entitlements (including paid maternity leave, sick leave, long service leave and recreation leave). You may claim up to 30% of eligible labour costs and these costs must be separately identified in the project budget as labour "on-costs".
- You should calculate eligible salary costs using the formula below:

$$\text{Eligible salary costs} = \text{Annual salary package} \times \frac{\text{Weeks spent on project}}{52 \text{ weeks}} \times \text{percentage of time spent on project}$$

- Equipment, provided you can demonstrate it is critical to meeting project objectives and outcome. The applicant must be prepared to meet all service and repair costs in relation to equipment funded. Equipment costs must not exceed 5% of the total grant amount.
- Applicants may request funding for a component of the research to be undertaken overseas if it can be demonstrated that the equipment/resources required for that component are not available in Australia and the component is critical to the successful completion of the research project. However, the expectation is that majority of the research activities and funding expenditure approved by CUREator will occur in Australia. Any overseas expenditure must first be approved by CUREator for it to be considered an eligible expense.
- Eligible contract expenditure is the cost of any agreed project activities that you contract others to do. These can include contracting another organisation, or an individual who is not an employee, but engaged under a separate contract. The maximum full-time equivalent salary costs for contractors employed through a contract, claims must not exceed a full-time equivalent salary of $175,000 per annum (including packaged components).
- All contractors must have a written contract prior to starting any project work—for example, a formal agreement, letter or purchase order which specifies the nature of the work they perform and the applicable fees, charges and other costs payable. Invoices from contractors must contain a detailed description of the nature of the work, the hours and hourly rates

involved, and any specific expenses paid. Invoices must directly relate to the agreed project, and the work must qualify as an eligible expense. The costs must also be reasonable and appropriate for the activities performed. Additionally, if you cannot provide records of contractor expenditure the relevant contract expense may not qualify as eligible expenditure.

5.1.2 Other eligible expenditure

Other eligible expenditures include costs directly related to the project activity that are not already being supported through any other sources, or where other Commonwealth, state or territory governments do not have primary responsibility, including:

- Financial auditing of project expenditure
- Costs you incur in order to obtain ethics and regulatory approvals during the project period. However, associated fees paid to the Commonwealth, state, territory and local governments are not eligible
- Insurances which are specifically required to cover the grant activity
- Accessing expertise that supports the protection of IP
- Other specific uses of funds may also be determined eligible, subject to approval by CUREator.

5.2 Ineligible expenditure

This section provides guidance on what is considered ineligible expenditure. Examples of ineligible expenditure include:

- Patent (filing) costs
- Institutional overheads and administrative costs
- Activities, equipment or supplies that are already being supported through other sources or where other Commonwealth, state or territory governments have primary responsibility
- Retrospective project costs or reimbursement of activities that commenced prior to the execution of a grant agreement
- Costs incurred prior to us notifying you that the cost is eligible
- Any in-kind contributions
- Maintenance or upgrades on buildings or structures
- Financing costs, including interest or debt financing
- Costs related to obtaining resources used on the project, including interest on loans, job advertising and recruiting, and contract negotiations
- Non-project related staff training and development costs
- Costs related to preparing the grant application, preparing any project reports (except costs of independent audit reports we require) and preparing any project variation requests
- Conference attendance, and associated travel
- Health insurance, travel insurance, foreign currency, airport and related travel taxes, passports and visas
- Entertainment and hospitality costs

- Personal subscriptions (e.g. personal journal subscriptions), or personal membership of professional organisations and groups, or airline club memberships
- Communications costs (mobiles, telephone calls)

This list is not exhaustive and applies only to the expenditure of the grant funds. Other costs may be ineligible where we decide that they do not directly support the achievement of the planned outcomes for the project or that they are contrary to the objective of the grant opportunity. You must ensure you have adequate funds to meet the costs of any ineligible expenditure associated with the project.

5.3 Justification of overseas spend

CUREator must approve all overseas expenditure. For funds to be spent overseas, the applicant must demonstrate why the activity can't be solely conducted in Australia. There are four allowable reasons. The activity:

- Requires facilities, expertise or equipment which are not available in Australia
- Would contravene a law relating to quarantine
- Requires a population (of living things) which are not available in Australia
- Requires access to geographical or geological features that are not available in Australia

Financial reasons alone are insufficient for an overseas activity to meet this condition.

6 Application and evaluation process

6.1 Application process

CUREator conducts a structured, multi-stage competitive application and evaluation process modelled on the established review processes of the Brandon BioCatalyst investment model. The process ensures independent expert review from the CUREator Investment Review Committee (IRC), international industry input from the International Pharma Advisory Committee (IPAC), and comprehensive due diligence to identify and support the most promising biotech opportunities.

All applications must be submitted online through the CUREator application portal: https://cureator.awardsplatform.com/

Applicants should be prepared to provide clear, detailed information at each stage of the process, from the initial expression of interest through to final due diligence and contracting. The application platform contains supporting information to help with preparing your submission. Please note incomplete or late applications will not be considered.

The CUREator selection and evaluation process follows a multi-stage process:

1. **Expression of Interest (EOI):** Eligible applicants submit a non-confidential EOI online to the CUREator application portal. Your EOI should articulate the opportunity and explain:
    - the research and its significance to human health or disease,
    - the unmet need or problem being addressed,
    - the potential target market and competitive advantage,
    - the technology and current stage of development,
    - the intellectual property position and strategy, and
    - a high-level proposed plan and budget, as well as commercialisation plan.

    The CUREator IRC evaluate applications against key selection criteria and meet to select a shortlist of applicants who are invited to proceed to the next stage.

2. **Full Application:** Shortlisted applicants will be invited to submit a full application and present to the CUREator IRC. The full application expands on the EOI and requires detailed project information, including a comprehensive project development plan and budget as well as responses to feedback from the CUREator IRC. Applicants will also need to deliver a presentation to the CUREator IRC either in person or virtually. Details and template documents will be provided to the shortlisted applicants. The CUREator IRC will evaluate the applications and pitches to inform and select a final shortlist to progress to the due diligence examination.

3. **Due Diligence:** The final shortlisted applicants will undergo due diligence. At this stage, the CUREator team will work closely with the applicants to conduct technical, clinical, regulatory,

IP, corporate and commercial due diligence and prepare a detailed project plan, including milestone structured activities with clear go/no-go decision points, feasible timelines and a detailed budget. CSIRO will provide a technical 'gap analysis' for individual therapeutic development programs to complement the diligence conducted. Projects will also be presented to the IPAC, a group of experienced global industry experts, for feedback, project specific input and introductions.

The CUREator IRC will consider due diligence and risk mitigation outcomes before confirming the selection of programs to receive grants. CUREator IRC independent committee members are required to endorse the programs selected.

Final endorsement and funding

Programs selected by the CUREator IRC for award are presented to the Brandon Capital Investment Committee to ensure they are within the investment mandate of the BMTI program. Programs endorsed by the Brandon Capital Investment Committee are presented to the Brandon BioCatalyst Board to ensure they meet governance requirements.

CUREator informs successful applicants of their award. SMEs must execute a grant agreement before funds are released, and project activities commence.

6.2 Selection criteria

Applications are assessed through a competitive and rigorous merit-based process conducted by the CUREator IRC, using the broad selection criteria outlined below to identify the most promising projects with strong scientific, clinical, and commercial potential.

Key criteria	Considerations
Project opportunity and market need	Addresses an unmet medical need, supported by evidence of market opportunity, target patient population, and current limitations of existing solutions.
Scientific and technical merit	Strength of the science/evidence-based data underpinning the project to support the hypothesis and planned next steps.
Competitive advantage and differentiation	The unique value proposition of the project is distinguished and/or improves on existing or emerging solutions.

IP position and strategy	Ability to protect the IP of the opportunity with a defendable and realistic IP strategy. The applicant owns or has exclusive rights to the underpinning IP and access to essential know-how.
Team and resourcing	Experienced, diverse team with access to the capabilities and expertise required to successfully deliver the project.
Project plan and budget	A credible, milestone-based plan with clear deliverables, quantitative go/no go decision gates, and appropriate timelines and budget.
Commercial pathway and outcomes	A well-defined strategy for further development, investability and commercialisation, supported by evidence of comparable transactions or precedents demonstrating relevance of the proposed commercial pathway.

6.3 Evaluation committees

As detailed above, the CUREator IRC evaluates and selects applications at all stages of the application process, and at the due diligence stage shortlisted applications are also reviewed by the International Pharma Advisory Committee (IPAC). The IRC are responsible for selecting and endorsing projects for funding.

The CUREator IRC compromises of independent members, a nationally representative sub-committee of the Brandon BioCatalyst IRC and CSIRO representatives. Collectively, the CUREator IRC has an international and national track record in the development and commercialisation of therapeutics. The IRC brings extensive experience across therapeutic preclinical R&D, clinical development, CMC, regulatory strategy, intellectual property, business development, venture investment and commercialisation.

The CUREator IPAC comprises of senior level international experts from the pharmaceutical, biotechnology and venture capital sectors, who bring extensive experience relevant to drug development and commercialisation. The IPAC provides advisory feedback and support for shortlisted opportunities.

All committee and advisory members are appointed under a strict CUREator Confidentiality and Conflict of Interest Policy. The committee declares and appropriately manages any conflicts, including those involving program participants, to ensure fair, unbiased decisions.

6.4 Key dates for the first round

2025 Funding Round	Dates
Expressions of Interest (EOI) open:	8 October 2025 at 1:00pm (AEDT)
EOI close:	4 December 2025 at 2:00pm (AEDT)
EOI outcome notifications and commencement of full application for shortlisted applicants:	From March 2026
Full applications due:	From mid-April 2026
Full application outcome notifications and commencement of due diligence period for shortlisted applicants:	From late May 2026
Successful SMEs funded and program activities commence:	From Q3 2026

Note: Key dates for the full application and due diligence period will be communicated to the shortlisted applicants.

7 Additional funding opportunities

CUREator is expanding its support for applicants through new collaborations with global pharmaceutical leaders, enabling them for the first time to opt-in via a single CUREator application to have their Expression of Interest reviewed by AbbVie and CSL for their respective programs and for potential investment through Brandon BioCatalyst.

In addition to the CUREator funding opportunity, applicants may choose to opt in to be considered for separate partnering and co-investment opportunities. Participation is entirely optional and will not influence the outcome of CUREator's assessment process. By opting in, you consent to CUREator sharing your application with the selected partner/s. Each partner operates its own process, timelines and criteria. While voluntarily accessed through a single application, the CUREator, AbbVie Green & Gold and CSL RAI awards and Brandon BioCatalyst investment opportunity remain separate programs, each with its own independent assessment process.

In the application form, you may select to opt-in to one or more partner opportunities that align with your project. Available opportunities:

AbbVie: Green & Gold Innovation Award

AbbVie's Green & Gold Innovation Award will support early-stage Australian biotech researchers and biotech companies with up to USD$1 million over two years.

AbbVie will initially provide USD$250,000 in capital to the winners, with the potential for top-up investments of up to USD$500,000 for high-performing SMEs, the program will focus on opportunities in immunology, oncology, neuroscience, obesity, and aesthetics. The selection and award are managed by AbbVie Ventures.

For more information: https://www.abbvie.com/science/partner-with-us/abbvie-ventures.html

CSL: Research Acceleration Initiative (RAI)

The CSL RAI award consists of a partnership with CSL that provides world-class scientists with up to USD$400,000 in funding over two years to support pre-clinical research programs. RAI awardees will also gain access to CSL's global network of industry experts to advance discoveries in key research areas of high unmet medical need, including immunology and transplant, hematology, cardiorenal and immunoglobulins. The selection and award are managed by CSL.

For more information: https://www.csl.com/csl-rai

Brandon BioCatalyst: Investment

Applicants may request consideration for equity investment by Brandon BioCatalyst.

For more information: https://brandonbiocatalyst.com/membership/investment-process/

8 Applicant support

During the EOI period, CUREator provides a range of support to help applicants prepare competitive, commercially focused applications.

Webinar

A national information session will be held online during the EOI period to explain program requirements and answer general questions.

The webinar details for the 2025 round are:

- Date: Monday 20th October
- Time: 1:00pm AEDT
- Register: https://us06web.zoom.us/webinar/register/WN_4hMdYGGnSqyhJnhuLu9jbA#/

The webinar recording will be made available online on the CUREator webpage: https://brandonbiocatalyst.com/cureator/

National roadshow series

The CUREator team will visit major cities across the Country to connect with researchers and founders and to lead a discussion on upcoming funding opportunities for research translation and commercialisation. Each session will introduce the new CUREator program and include a moderated panel offering practical insights on preparing a strong, competitive application, followed by a Q&A session. Networking events will accompany each session.

To register for an event in Adelaide, Brisbane, Melbourne, Sydney or Perth during October and November 2025, visit: https://brandonbiocatalyst.com/cureator/events/

EOI meetings with applicants

Interested applicants will have an opportunity to book a 30-minute meeting with the CUREator team to discuss their application or ask any general questions during the EOI period.

To arrange a meeting, please book a 30-minute slot with one of the CUREator team members at: https://scheduler.zoom.us/d/195fif99/cureator-2025-expression-of-interest-meeting

Please note discussions will be centred around helping applicants position their proposal towards commercially orientated outcomes or to seek additional clarity related to funding requirements. The CUREator team will not be able to give project specific advice, and all advice will be general in nature.

9 FAQs

How many funding rounds will CUREator run?

CUREator will run two open, competitive funding rounds for Stage 1 funding with these rounds opening in 2025 and 2026.

The first funding round opens for Expression of Interest on the 8th of October 2025.

Can I download the application to work offline?

Yes, you may download a pdf template from the CUREator application portal. However, if working offline, we strongly encourage applicants to review the application online in detail before submission. There are conditional questions, which may not appear on the template. Please note the key criteria to be addressed is listed on the downloadable template.

Is this research funding, a commercial grant or will CUREator take equity?

CUREator provides commercial grant funding (equity free) to projects. This funding is best considered as non-dilutive capital rather than a research grant. This means successful projects will receive tranche funding, aligned with developmental and/or commercial milestones, that will be defined and agreed together with CUREator as part of the due diligence process.

CUREator retain no legal rights, liens, or rights of refusal over any participating SMEs technology. SMEs accepted into CUREator will need to demonstrate that all background IP and project IP flows to the successful SME.

Can funding be used to cover the costs associated with IP protection, filing etc?

If the IP strategy is part of your approved project activities, then some IP related costs can be covered. For example, if the SME is seeking IP advice from firms and IP professionals with experience in supporting innovations specific to your technology, then this may be supported. The program will not fund any direct costs of patent/trademark/copyright, registration fees and licenses, which are deemed ineligible expenditures within the MRFF funding guidelines. Please refer to the funding guidelines for eligible expenditure details.

Can I re-apply, or submit an application if I have previously submitted a proposal to CUREator, CUREator+ or CUREator+ Dementia & Cognitive Decline that was not successful?

We encourage previous applicants whether successful or unsuccessful recipients of CUREator, CUREator+ or other funding schemes to apply for this CUREator program. Applicants are requested to describe any feedback they have previously received and how the proposal addresses the feedback.

You do not need to have applied to these programs previously to be considered for funding through this BMTI program delivered by CUREator.

We already have MRFF funding, can we still apply?

Yes, however, you cannot 'double dip' on activities already funded under an MRFF agreement or any other funding for that matter. Projects must ensure clear delineation of how CUREator funding will be utilised outside of 'business-as-usual' activities and existing or future committed funding.

What happens if my project has grant funding, equity investment, or matching capital from other sources?

Leveraging matching capital (and in-kind support) will be well regarded.

Applicants should ensure that it is clear what the CUREator funding will be used to achieve and how this is measurably distinct from use of any other funding or support from other sources. Applicants will be required to delineate how funds will be utilised outside "business-as-usual" activities and applicants must ensure they have sufficient runway and resources to fully deliver the program.

How confidential is the application process?

All application information is treated commercial in confidence. All members of the selection and advisory committees operate under strict confidentiality and conflicts of interest agreements.

The EOI is a non-confidential application, so it is not expected that you will disclose confidential information to submit a successful application. However, it is imperative that you can share enough technical information to demonstrate differentiation and novelty. If confidential information is provided, please preface this with [Confidential].

Can I get feedback on my submitted EOI application?

Unsuccessful EOI applications will be advised as soon as possible during the review process and provided with general feedback. However, owing to the volume of applications we receive, unsuccessful applicants are not expected to receive project specific feedback at the EOI stage.

What will the full application form entail?

The full application will expand on the information provided in the EOI to provide a full outline of the project. Details and template documents will be provided via the CUREator application platform upon the opening of the full application period to shortlisted applicants.

What should I do if I have challenges with the application portal?

Although we strive to offer a great application experience, sometimes these things happen. Please get in touch by emailing the CUREator team at info@cureator.com.au with specific details of the issue you are facing.

Can I talk to someone about the program and my application?

Yes. CUREator will host a national webinar and roadshow during the EOI periods. Interested SMEs, innovators, researchers and commercialisation professionals are encouraged to book a 30-minute meeting with the CUREator team to discuss their opportunity.

To arrange a meeting to discuss your opportunity or ask any general enquiries, please contact the CUREator team at: info@cureator.com.au

10 Contact information

For more information about CUREator visit: https://brandonbiocatalyst.com/cureator/

For any enquiries, please contact info@cureator.com.au